
Concentration (µg/mL)
0.000
0.002
0.004
0.006
0.008
0
20
40
60
80
100
120
140
Time (day)

FIG. 1


Simulated Hazard of Grade 2+ CRS
0.2
0.15
0.1
0.05
0
Reference Regimen
Safe Delayed Regimen
Unsafe Delayed Regimen
0
7
14
21
28
35
Time (Days)

FIG. 2


Proportion of patients that can safely resume dosing after delay relative to planned dosing schedule
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0
4
8
12
16
20
24
28
Amount of Dosing Delay from Planned Schedule (Weeks)
Missed intermediate dose
Missed 1st full dose
Missed 2nd full dose
Missed full dose after C1

FIG. 3


Cohort
Nominal dosing schedule
Delayed dosing, re-priming not required
Delayed dosing, re-priming required
10.000
0.100
0.001
Concentration (ug/mL)
0
4
8
12
16
20
24
28
32
36
40
44
48
52
56
60
64
Time (Week)

FIG. 4


Cohort
Nominal dosing schedule
Delayed dosing, re-priming not required
Delayed dosing, re-priming required
10.000
0.100
0.001
Concentration (ug/mL)
0
4
8
12
16
20
24
28
32
36
40
44
48
52
56
60
64
Time (Week)

FIG. 5


Cohort
Nominal dosing schedule
Delayed dosing, re-priming not required
Delayed dosing, re-priming required
10.000
0.100
0.001
Concentration (ug/mL)
0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72
Time (Week)

FIG. 6


Cohort
Nominal dosing schedule
Delayed dosing, re-priming not required
Delayed dosing, re-priming required
10.000
0.100
0.001
Concentration (ug/mL)
0
4
8
12
16
20
24
28
32
36
40
44
48
52
56
60
64
68
Time (Week)

FIG. 7


Cohort
Nominal dosing schedule
Delayed dosing, re-priming not required
Delayed dosing, re-priming required
10.000
0.100
0.001
Concentration (ug/mL)
0
4
8
12
16
20
24
28
32
36
40
44
48
52
56
60
64
68
Time (Week)

FIG. 8